Protacs e Impurezze

Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays …

AK-2292: potent STAT5 PROTAC degrader, DC50 0.10 μM, degrades STAT5A/B, may shrink leukemia tumors in …

Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.

DB0614 degrades 26 kinases including AAK1 and CDK6, targeting aberrant activity in disease research.

SHP2 protein degrader-2 (SHP2-D26), a PROTAC degrader targeting the SHP2 protein, effectively diminishes its expression …

PROTAC Axl Degrader 2: potent, selective, IC50 1.61µM; inhibits cell growth & migration, induces mehuosis.

PROTAC BP3 selectively degrades HSP90, inhibits breast cancer growth (DC50=0.99µM), CRBN-dependent.

DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].

MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, …

PZ703b hydrochloride, a Bcl-xl PROTAC, triggers apoptosis and halts cancer growth; used in bladder cancer …

PROTAC CBP/P300 Degrader-1 effectively reduces cancer cell viability by degrading CBP/P300.

PROTAC BRD4 Degrader-19 (compound 176) is a proteolysis-targeting chimera (PROTAC) designed to specifically degrade the …

(S,R,S)-AHPC-C2-amide targets Smad3 degradation and boosts HIF-α; it has anti-fibrotic and renal protective roles.

dTAGV-1 TFA targets and degrades mutant FKBP12 F36V fusion proteins effectively.

JB170: potent PROTAC, degrades AURORA-A (DC50=28nM), binds better to AURORA-A (EC50=193nM) than B, causes S-phase …

dBET23 is a BRD4 degrader.

dTAG-47 targets FKBP12 F36V for protein degradation, useful in basal-like breast cancer research.

PROTAC BRD4 Degrader-8: BRD4 inhibitor with IC50s of 1.1/1.4 nM for BD1/BD2, degrades BRD4 in …

SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL …

PROTAC Bcl-xL degrader-2, based on von Hippel-Lindau ligand, is a potent degrader of Bcl-xL (a …